Home › Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...
 

Keywords :   


Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...

2015-05-30 21:49:00| Logistics - Topix.net

Clovis Oncology today announced updated Phase 2 results from two ongoing clinical studies with rucaparib: ARIEL2 and Study 10. Rucaparib is the Company's investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of advanced ovarian cancer, specifically in patients with BRCA mutations and other DNA repair deficiencies beyond BRCA, commonly referred to as "BRCA-like." Updated data from the ARIEL2 study in 204 patients with advanced ovarian cancer are being presented Monday in an oral presentation by Professor Iain McNeish at the 2015 American Society of Clinical Oncology annual meeting in Chicago.

Tags: studies phase cancer ovarian

Category:Transportation and Logistics

Latest from this category

All news
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
Transportation and Logistics »
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Kim Madigan to chair 2025 FTA Fall Technical Conference
05.11PM responds to Sir Alan Bates after repeated requests
More »